AD Outcomes Improved With Lebrikizumab and Topical Steroids

The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.
Medscape Medical News

source https://www.medscape.com/viewarticle/986934?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost